Current primary open-angle glaucoma treatments and future directions

Gabriel Beidoe, Shaker A MousaPharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USAAbstract: Primary open-angle glaucoma (POAG) is a leading cause of blindness with no known cure. Management of the disease focuses on lowering intraocular pressure (I...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Beidoe G, Mousa SA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/32579206dcce4dcfb48899b36740727a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:32579206dcce4dcfb48899b36740727a
record_format	dspace
spelling	oai:doaj.org-article:32579206dcce4dcfb48899b36740727a2021-12-02T02:54:59ZCurrent primary open-angle glaucoma treatments and future directions1177-54671177-5483https://doaj.org/article/32579206dcce4dcfb48899b36740727a2012-10-01T00:00:00Zhttp://www.dovepress.com/current-primary-open-angle-glaucoma-treatments-and-future-directions-a11335https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Gabriel Beidoe, Shaker A MousaPharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USAAbstract: Primary open-angle glaucoma (POAG) is a leading cause of blindness with no known cure. Management of the disease focuses on lowering intraocular pressure (IOP) with current classes of drugs like prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. These treatments have not helped all patients. Some patients continue to experience deterioration in the optic nerve even though their IOPs are within the normal range. New views have surfaced about other pathophysiological processes (such as oxidative stress, vascular dysfunction, and retinal cell apoptosis) being involved in POAG progression, and adjunctive treatments with drugs like memantine, bis(7)-tacrine, nimodipine, and mirtogenol are advocated. This review examines the current and proposed treatments for POAG. Some of the proposed drugs (bis(7)-tacrine, nimodipine, vitamin E, and others) have shown good promise, mostly as monotherapy in various clinical trials. It is recommended that both the current and proposed drugs be put through further robust trials in concurrent administration and evaluated.Keywords: bis(7)-tacrine, betaxolol, memantine, mirtogenol, POAG, timolol, travoprostBeidoe GMousa SADove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2012, Iss default, Pp 1699-1707 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Beidoe G Mousa SA Current primary open-angle glaucoma treatments and future directions
description	Gabriel Beidoe, Shaker A MousaPharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USAAbstract: Primary open-angle glaucoma (POAG) is a leading cause of blindness with no known cure. Management of the disease focuses on lowering intraocular pressure (IOP) with current classes of drugs like prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. These treatments have not helped all patients. Some patients continue to experience deterioration in the optic nerve even though their IOPs are within the normal range. New views have surfaced about other pathophysiological processes (such as oxidative stress, vascular dysfunction, and retinal cell apoptosis) being involved in POAG progression, and adjunctive treatments with drugs like memantine, bis(7)-tacrine, nimodipine, and mirtogenol are advocated. This review examines the current and proposed treatments for POAG. Some of the proposed drugs (bis(7)-tacrine, nimodipine, vitamin E, and others) have shown good promise, mostly as monotherapy in various clinical trials. It is recommended that both the current and proposed drugs be put through further robust trials in concurrent administration and evaluated.Keywords: bis(7)-tacrine, betaxolol, memantine, mirtogenol, POAG, timolol, travoprost
format	article
author	Beidoe G Mousa SA
author_facet	Beidoe G Mousa SA
author_sort	Beidoe G
title	Current primary open-angle glaucoma treatments and future directions
title_short	Current primary open-angle glaucoma treatments and future directions
title_full	Current primary open-angle glaucoma treatments and future directions
title_fullStr	Current primary open-angle glaucoma treatments and future directions
title_full_unstemmed	Current primary open-angle glaucoma treatments and future directions
title_sort	current primary open-angle glaucoma treatments and future directions
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/32579206dcce4dcfb48899b36740727a
work_keys_str_mv	AT beidoeg currentprimaryopenangleglaucomatreatmentsandfuturedirections AT mousasa currentprimaryopenangleglaucomatreatmentsandfuturedirections
_version_	1718402031438266368

Current primary open-angle glaucoma treatments and future directions

Ejemplares similares